{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T23:58:20Z","timestamp":1773187100342,"version":"3.50.1"},"reference-count":72,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,1,25]],"date-time":"2022-01-25T00:00:00Z","timestamp":1643068800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med. Technol."],"abstract":"<jats:p>Health technology assessment (HTA) is intended to determine the value of health technologies and, once a technology is recommended for funding, bridge clinical research and practice. Understanding the values and beliefs expressed by patients and health professionals can help guide this knowledge transfer and work toward managing the expectations of end users. We gathered patient and patient group leader experiences to gain insights into the roles that patients and patient advocacy groups are playing. We argue that through partnerships and co-creation between HTA professionals, researchers and patient advocates we can strengthen the HTA process and better align with service delivery where person-centered care and shared decision making are key elements. Patient experiences and knowledge are important to the democratization of evidence and the legitimacy of HTAs. Patient preference studies are used to balance benefits with potential harms of technologies, and patient-reported outcomes (PROs) can measure what matters to patients over time. A change in culture in HTA bodies is occurring and with further transformative thinking patients can be involved in every step of the HTA process. Patients have a right to be involved in HTAs, with patients' values central to HTA deliberations on a technology and where patients can provide valuable insights to inform HTA decision-making; and in ensuring that HTA methodologies evolve. By evaluating the implementation of HTA recommendations we can determine how HTA benefits patients and their communities. Our shared commitment can positively effect the common good and provide benefits to individual patients and their communities.<\/jats:p>","DOI":"10.3389\/fmedt.2021.796344","type":"journal-article","created":{"date-parts":[[2022,1,25]],"date-time":"2022-01-25T07:23:35Z","timestamp":1643095415000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":9,"title":["Can We Afford to Exclude Patients Throughout Health Technology Assessment?"],"prefix":"10.3389","volume":"3","author":[{"given":"Janet L.","family":"Wale","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Chandler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Deborah","family":"Collyar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dominique","family":"Hamerlijnck","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roberto","family":"Saldana","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zack","family":"Pemberton-Whitely","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2022,1,25]]},"reference":[{"key":"B1","unstructured":"How COVID-19 Is Revolutionizing Health Care Around the World\n            YameyG\n            PaiM\n          34831725Time Magazine.2021"},{"key":"B2","unstructured":"McGurnS\n          DIA Global ForumChanging Landscape of Evidence Charting New Assessment Pathways. Q&A with Canadian Agency for Drugs Technologies in Health (CADTH)2021"},{"key":"B3","unstructured":"Patient Involvement Strategy 2021-25"},{"key":"B4","unstructured":"Partners & Networks. Patients and Consumers"},{"key":"B5","unstructured":"Patient Engagement"},{"key":"B6","unstructured":"Delivering Value to Canadians. Canadian Agency for Drugs and Technology in Health (CADTH)"},{"key":"B7","doi-asserted-by":"publisher","first-page":"2477","DOI":"10.1056\/NEJMp1011024","article-title":"What is value in health care?","volume":"363","author":"Porter","year":"2010","journal-title":"N Engl J Med."},{"key":"B8","doi-asserted-by":"publisher","first-page":"597","DOI":"10.2471\/BLT.06.031724","article-title":"The knowledge-value chain: a conceptual framework for knowledge translation in health","volume":"8","author":"Landry","year":"2006","journal-title":"Bull World Health Organ."},{"key":"B9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1017\/S0266462317000241","article-title":"Why patients should be involved in health technology assessment","volume":"1","author":"Wale","year":"2017","journal-title":"Int J Technol Assess Health Care."},{"key":"B10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1017\/S0266462319000825","article-title":"The 'Top 10' challenges for health technology assessment: INAHTA viewpoint","volume":"36","author":"O'Rourke","year":"2020","journal-title":"Int J Technol Assess Health Care."},{"key":"B11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s40900-020-00248-9","article-title":"Patients and public are important stakeholders in health technology assessment but the level of involvement is low - a call to action","volume":"7","author":"Wale","year":"2021","journal-title":"Res Involv Engagem."},{"key":"B12","unstructured":""},{"key":"B13","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1017\/S0266462320000215","article-title":"The new definition of health technology assessment: a milestone in international collaboration","volume":"36","author":"O'Rourke","year":"2020","journal-title":"Int J Technol Assess Health Care."},{"key":"B14","doi-asserted-by":"publisher","first-page":"228","DOI":"10.34172\/ijhpm.2020.46","article-title":"Deliberative processes by health technology assessment agencies: a reflection on legitimacy, values and patient and public involvement: Comment on \u201cUse of evidence-informed deliberative processes by health technology assessment agencies around the globe.\u201d","volume":"10","author":"Goetghebeur","year":"2020","journal-title":"Int J Health Policy Manag"},{"key":"B15","doi-asserted-by":"publisher","first-page":"1518","DOI":"10.1016\/j.socscimed.2010.01.036","article-title":"\u201cIt all depends\u201d: conceptualizing public involvement in the context of health technology assessment agencies","volume":"70","author":"Gauvin","year":"2010","journal-title":"Soc Sci Med."},{"key":"B16","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1017\/S0266462316000362","article-title":"Public and patient involvement in health technology assessment: a framework for action","volume":"32","author":"Abelson","year":"2016","journal-title":"Int J Technol Assess Health Care."},{"key":"B17","doi-asserted-by":"publisher","first-page":"e36","DOI":"10.1017\/S0266462321000064","article-title":"Patient and public involvement in health technology assessment: update of a systematic review of international experiences","volume":"37","author":"Gagnon","year":"2021","journal-title":"Int J Technol Assess Health Care."},{"key":"B18","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1215\/03616878-7530825","article-title":"\u201cGetting to the table\u201d: changing ideas about public and patient involvement in Canadian drug assessment","volume":"44","author":"Boothe","year":"2019","journal-title":"J Health Polit Policy Law."},{"key":"B19","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1017\/S1744133121000013","article-title":"(Re)defining legitimacy in Canadian drug assessment policy? Comparing ideas over time","volume":"16","author":"Boothe","year":"2021","journal-title":"Health Econ Policy Law."},{"key":"B20","doi-asserted-by":"publisher","first-page":"e37","DOI":"10.1017\/S0266462321000088","article-title":"An institutional ethnographic analysis of public and patient engagement activities at a national health technology assessment agency","volume":"37","author":"Bidonde","year":"2021","journal-title":"Int J Technol Assess Health Care."},{"key":"B21","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1017\/S0266462320000513","article-title":"Developing an agency's position with respect to patient involvement in health technology assessment: the importance of the organizational culture","volume":"36","author":"Cleemput","year":"2020","journal-title":"Int J Technol Assess Health Care."},{"key":"B22","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1071\/PY16129","article-title":"Understanding the factors that make public participation effective in health policy and planning: a realist synthesis","volume":"23","author":"Pagatpatan","year":"2017","journal-title":"Aust J Prim Health."},{"key":"B23","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/s40900-016-0052-9","article-title":"HTAi Patient and Citizen Involvement in HTA Interest Group, Patient Involvement and Education Working Group. Patient advocate perspectives on involvement in HTA: an international snapshot","volume":"3","author":"Scott","year":"2017","journal-title":"Res Involv Engagem."},{"key":"B24","doi-asserted-by":"publisher","first-page":"e15","DOI":"10.1017\/S0266462320000860","article-title":"Expertise, experience, and excellence. Twenty years of patient involvement in health technology assessment at NICE: an evolving story","volume":"37","author":"Norburn","year":"2020","journal-title":"Int J Technol Assess Health Care."},{"key":"B25","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1097\/PPO.0000000000000466","article-title":"Time to treat financial toxicity for patients","volume":"26","author":"Collyar","year":"2020","journal-title":"Cancer J"},{"key":"B26","unstructured":"Health Intervention and Technology Assessment in Support of Universal Health Coverage2014"},{"key":"B27","doi-asserted-by":"publisher","first-page":"511","DOI":"10.7326\/M20-6625","article-title":"Masks and face coverings for the lay public: a narrative update","volume":"174","author":"Czypionka","year":"2021","journal-title":"Ann Intern Med."},{"key":"B28","doi-asserted-by":"publisher","first-page":"2643","DOI":"10.1016\/j.pec.2021.07.022","volume":"104","author":"Greenhalgh","year":"2021","journal-title":"Moral uncertainty: a case study of Covid-19. Patient Educ Couns"},{"key":"B29","unstructured":"2021"},{"key":"B30","unstructured":"Plenary \u201cPatients at the Heart of Innovation.\u201d"},{"key":"B31","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/s40900-016-0018-y","article-title":"It's not evidence, it's insight: bringing patients' perspectives into health technology appraisal at NICE","volume":"2","author":"Staley","year":"2016","journal-title":"Res Involv Engagem."},{"key":"B32","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1017\/S0266462320000240","article-title":"Exploration of the visibility of patient input in final recommendation documentation for three health technology assessment bodies","volume":"36","author":"Wale","year":"2020","journal-title":"Int J Technol Assess Health Care."},{"key":"B33","doi-asserted-by":"publisher","first-page":"e12","DOI":"10.1017\/S0266462320002202","article-title":"Strengthening patient outcome evidence in health technology assessment: a coproduction approach","volume":"37","author":"Rasburn","year":"2021","journal-title":"Int J Technol Assess Health Care."},{"key":"B34","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1007\/s40271-018-0325-5","article-title":"Putting patients at the centre of healthcare: progress and challenges for health technology assessments","volume":"11","author":"Facey","year":"2018","journal-title":"Patient."},{"key":"B35","doi-asserted-by":"publisher","first-page":"e33","DOI":"10.1017\/S0266462320002214","article-title":"Evaluation of the impact of patient input in health technology assessments at NICE","volume":"37","author":"Livingstone","year":"2021","journal-title":"Int J Technol Assess Health Care."},{"key":"B36","doi-asserted-by":"publisher","first-page":"e46","DOI":"10.1017\/S026646232100012X","article-title":"Mind the evidence gap: the use of patient-based evidence to create \u201ccomplete HTA\u201d in the twenty-first century","volume":"37","author":"Staniszewska","year":"2021","journal-title":"Int J Technol Assess Health Care."},{"key":"B37","unstructured":"CDER Patient-Focused Drug Development"},{"key":"B38","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1007\/s40271-019-00400-y","article-title":"Patient preferences in the medical product lifecycle","volume":"13","author":"Whitty","year":"2019","journal-title":"Patient"},{"key":"B39","doi-asserted-by":"publisher","first-page":"543046","DOI":"10.3389\/fmed.2020.543046","article-title":"Use of patient preference information in benefit\u2013risk assessment, health technology assessment, and pricing and reimbursement decisions: a systematic literature review of attempts and initiatives","volume":"7","author":"Chachoua","year":"2020","journal-title":"Front Med."},{"key":"B40","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.3389\/fphar.2019.01009","article-title":"Factors and situations affecting the value of patient preference studies: semi-structured interviews in Europe and the US","volume":"10","author":"Whichello","year":"2019","journal-title":"Front Pharmacol."},{"key":"B41","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1177\/2168479019871519","article-title":"FDA reported use of patient experience data in 2018 drug approvals","volume":"54","author":"Kieffer","year":"2019","journal-title":"Ther Innov Regul Sci"},{"key":"B42","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/j.jval.2018.09.2842","article-title":"A review of patient-reported outcomes labeling for oncology drugs approved by the FDA and the EMA (2012-2016)","volume":"2","author":"Gnanasakthy","year":"2019","journal-title":"Value Health."},{"key":"B43","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1007\/s40271-019-00407-5","article-title":"A qualitative research for defining meaningful attributes for the treatment of inflammatory bowel disease from the patient","volume":"3","author":"Louis","year":"2020","journal-title":"Perspective Patient."},{"key":"B44","doi-asserted-by":"publisher","first-page":"82","DOI":"10.3389\/fmed.2019.00082","article-title":"Patient preference studies during early drug development: aligning stakeholders to ensure development plans meet patient needs","volume":"6","author":"Cook","year":"2019","journal-title":"Front Med."},{"key":"B45","doi-asserted-by":"publisher","first-page":"686165","DOI":"10.3389\/fmed.2021.686165","article-title":"Patient preferences for multiple myeloma treatments: a multinational qualitative study","volume":"8","author":"Janssens","year":"2021","journal-title":"Front Med."},{"key":"B46","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1038\/d41573-019-00088-7","article-title":"Harnessing the patient voice in real-world evidence: The essential role of patient-reported outcomes","volume":"18","author":"Calvert","year":"2019","journal-title":"Nat Rev Drug Discov"},{"key":"B47","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1111\/hex.12997","article-title":"Including the patient voice in the development and implementation of patient-reported outcomes in cancer clinical trials","volume":"23","author":"Addario","year":"2019","journal-title":"Health Expect"},{"key":"B48","doi-asserted-by":"publisher","first-page":"118","DOI":"10.18553\/jmcp.2020.20313","article-title":"Improving patient-reported measures in oncology: a payer call to action","volume":"1","author":"Schmidt","year":"2021","journal-title":"J Manag Care Spec Pharm."},{"key":"B49","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1111\/hex.12594","article-title":"Decision making in NICE single technology appraisals: how does NICE incorporate patient perspectives?","volume":"1","author":"Hashem","year":"2018","journal-title":"Health Expect."},{"key":"B50","unstructured":"764\n            OkanO\n            BauerU\n            Levin-ZamirD\n            PinheiroP\n            S\u00f8rensenK\n          Research, Practice Policy Across the Lifespan. BristolPolicy PressInternational Handbook of Health Literacy2019"},{"key":"B51","unstructured":"National Standards for Public Involvement"},{"key":"B52","unstructured":"EUPATIToolbox"},{"key":"B53","unstructured":""},{"key":"B54","doi-asserted-by":"publisher","first-page":"3663","DOI":"10.2217\/fon-2021-0856","article-title":"The importance and value of engaging patients in cancer research","volume":"28","author":"Collyar","year":"2021","journal-title":"Future Oncol."},{"key":"B55","doi-asserted-by":"publisher","first-page":"4801","DOI":"10.1002\/cncr.27485","article-title":"Patient advocates' role in clinical trials: perspectives from Cancer and Leukemia Group B investigators and advocates","volume":"18","author":"Katz","year":"2012","journal-title":"Cancer."},{"key":"B56","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1136\/bmjinnov-2018-000317","article-title":"Co-creation of patient engagement quality guidance for medicines development: an international multistakeholder initiative","volume":"1","author":"Deane","year":"2019","journal-title":"BMJ Innov."},{"key":"B57","article-title":"EFPIA code of practice on relationships between the pharmaceutical industry and patient organisations","year":"2011"},{"key":"B58","doi-asserted-by":"publisher","first-page":"e50","DOI":"10.1017\/S0266462321000167","article-title":"Development of an international template to support patient submissions in Health Technology Assessments","volume":"1","author":"Cook","year":"2021","journal-title":"Int J Technol Assess Health Care."},{"key":"B59","first-page":"299","article-title":"Germany","author":"Haefner","year":"2017"},{"key":"B60","doi-asserted-by":"publisher","first-page":"e11","DOI":"10.1017\/S0266462320002123","article-title":"L'Esp\u00e9rance A, Lochhead L, Ganache I, Roy D. Developing recommendations for the diagnosis and treatment of Lyme disease: the role of the patient's perspective in a controversial environment","volume":"37","author":"Pomey","year":"2020","journal-title":"Int J Technol Assess Health Care."},{"key":"B61","unstructured":"O'RourkeB\n            OrsiniLS\n            GuerinoJ\n          COVID-19: Challenges and Opportunities for the Global Health Technology Assessment Community"},{"key":"B62","doi-asserted-by":"publisher","first-page":"e19","DOI":"10.1017\/S0266462320002251","article-title":"Creating a patient and community advisory committee at the Canadian Agency for Drugs and Technologies in Health","volume":"37","author":"Berglas","year":"2021","journal-title":"Int J Technol Assess Health Care."},{"key":"B63","unstructured":"Geneva: World Health Organization62003"},{"key":"B64","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.1016\/j.healthpol.2020.06.010","article-title":"Who should be given priority for public funding?","volume":"124","author":"Bae","year":"2020","journal-title":"Health Policy."},{"key":"B65","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1002\/ueg2.12105","article-title":"Inflammatory bowel disease integral care units: evaluation of a nationwide quality certification programme. The GETECCU experience","volume":"9","author":"Barreiro-de Acosta","year":"2021","journal-title":"United Eur Gastroenterol J"},{"key":"B66","unstructured":"CleemputI\n            DauvrinM\n            KohnL\n            MistiaenP\n            ChristiaensW\n            L\u00e9anardC\n          KCE Reports 320: Position of KCE on Patient Involvement in Health Care Policy Research.2019"},{"key":"B67","doi-asserted-by":"publisher","first-page":"E3","DOI":"10.1017\/S0266462320001956","article-title":"Serrano Aguilar P. Development of a decisional flowchart for meaningful patient involvement in health technology assessment","volume":"37","author":"Toledo-Ch\u00e1varri","year":"2021","journal-title":"Int J Tech Assess Health Care."},{"key":"B68","unstructured":"Revalmed(Spanish),.\n          2020"},{"key":"B69","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1017\/S0266462318000569","article-title":"Multi-criteria decision analysis as a decision-support tool for drug evaluation: a pilot study in a pharmacy and therapeutics committee setting","volume":"34","author":"Rold\u00e1n","year":"2018","journal-title":"Int J Technol Assess Health Care."},{"key":"B70","doi-asserted-by":"publisher","first-page":"699466","DOI":"10.3389\/fphar.2021.699466","article-title":"The evolution of AIFA registries to support managed entry agreements for orphan medicinal products in Italy","volume":"12","author":"Xoxi","year":"2021","journal-title":"Front Pharmacol."},{"key":"B71","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1093\/ibd\/izz126","article-title":"Improving quality of care in inflammatory bowel disease through patients' eyes: IQCARO project","volume":"26","author":"Calvet","year":"2020","journal-title":"Inflamm Bowel Dis."},{"key":"B72","doi-asserted-by":"publisher","first-page":"3","DOI":"10.35680\/2372-0247.1091","article-title":"Patient leadership: taking patient experience to the next level?","volume":"2","author":"McNally","year":"2015","journal-title":"Patient Exp J."}],"container-title":["Frontiers in Medical Technology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmedt.2021.796344\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,25]],"date-time":"2022-01-25T07:23:40Z","timestamp":1643095420000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmedt.2021.796344\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,25]]},"references-count":72,"alternative-id":["10.3389\/fmedt.2021.796344"],"URL":"https:\/\/doi.org\/10.3389\/fmedt.2021.796344","relation":{},"ISSN":["2673-3129"],"issn-type":[{"value":"2673-3129","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,25]]},"article-number":"796344"}}